Noble Pharma

Name

Noble Pharma

Legal name

Noble Pharma LLC

Website

https://noblepharmallc.com/

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Menomonie

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D

Revenue model

1. Contract Manufacturing Services: Revenue generated through contract manufacturing agreements with pharmaceutical companies. Noble Pharma provides full-service CDMO capabilities including formulation development, clinical supplies manufacturing, commercial manufacturing, and packaging services on a contractual basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Noble Pharma is a turn-key pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end production services from early-stage formulation and process development through clinical supplies manufacturing, commercial manufacturing, packaging, analytical/stability testing, and regulatory support. The Menomonie, Wisconsin facility serves both human and animal pharmaceutical clients and produces multiple dosage forms including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.

Product overview

Noble Pharma is a turnkey pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from concept to shelf-ready products. The company operates a single integrated platform comprising six core service modules: Formulation & Process Development, Clinical Supplies Manufacturing, Contract Manufacturing & Packaging, Analytical Development & Stability Program, Regulatory Support, and Product Life Cycle Management Services. The facility specializes in both human and animal pharmaceuticals, producing various dosage forms including suspensions, liquids, tablets, boluses, powders, gels, pastes, creams, and ointments.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation & Process Development ICH Q8-based formulation development, analytical development, process development, and package development services, including preformulation development and preclinical studies, for pharmaceutical companies developing human or animal drug products.
• Clinical Supplies Manufacturing Agile manufacturing of clinical supply batches at any clinical scale, supporting multiple dosage forms, with preliminary process identification and formulation/process optimization for pharmaceutical sponsors.
• Contract Manufacturing & Packaging Contract commercial-scale manufacturing and packaging with dedicated process areas for specific technologies and dosage forms, including product serialization and child-resistant packaging for pharmaceutical companies.
• Analytical Development & Stability Program GLP-philosophy-based analytical services including method development and routine testing, plus ICH-based stability storage and stability testing for pharmaceutical products.
• Regulatory Support Regulatory filing strategy, CMC data package advisory, dossier preparation, and regulatory query response support for pharmaceutical sponsors pursuing market authorization.
• Product Life Cycle Management Services Quality-by-design-based development, integrated technology transfer, validation approach, continued process verification, and process improvement services across a pharmaceutical product's commercial life cycle.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• ParnellcoreStrategic or Co-development Partner · 26 November 2025Parnell, a veterinary pharmaceutical company, acquired Noble Pharma LLC on November 26, 2025. The acquisition enhances Parnell's manufacturing capabilities, supply continuity, and growth potential in the U.S. market by adding Noble Pharma's FDA- and DEA-accredited Menomonie, Wisconsin manufacturing facility to their operations.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Recipharm: European CDMO offering formulation development, clinical supply, and commercial manufacturing of oral and other dosage forms. Closely comparable service model, customer base (human and animal pharma sponsors), and regulatory positioning.
• Cambrex: Specialty CDMO focused on small-molecule API and finished dosage form development/manufacturing. Directly comparable in therapeutic focus and service scope, with broader site footprint.
• Alcami: US-based mid-sized CDMO providing formulation, analytical, clinical manufacturing, and commercial supply. Closely comparable end-to-end service offering and scale band to Noble Pharma.
• Curia (formerly AMRI): CDMO offering drug substance, drug product, and analytical services for small and large molecules. Overlaps with Noble's formulation-to-commercial pipeline, particularly in oral solid and liquid dosage forms.
• Bora Pharmaceutical: CDMO specializing in oral solid dosage forms, with US facilities offering commercial manufacturing, packaging, and serialization. Directly comparable in dosage form focus and end-to-end CDMO service model.
• Hovione: Specialty CDMO offering formulation development, clinical manufacturing, and commercial supply of small-molecule drug products. Comparable service portfolio to Noble with deeper particle engineering and inhalation expertise.

Broad incumbents

• Catalent: Global pharmaceutical CDMO offering formulation, clinical supply, commercial manufacturing and packaging across dosage forms. Directly comparable end-to-end service portfolio, but at vastly greater scale across many sites globally.
• Patheon (Thermo Fisher Scientific): Pharma services division of Thermo Fisher providing drug development and commercial manufacturing, including CDMO services. Overlaps directly with Noble's formulation, clinical supply, and commercial manufacturing capabilities at far greater scale.
• Lonza: Swiss-headquartered global CDMO with extensive small-molecule drug product and API manufacturing. Competes for the same small-molecule formulation and commercial manufacturing work Noble targets, with much broader scale and geographic reach.

Regional players

• Vets Plus: Animal-health manufacturer operating out of Menomonie, WI, listed as the operating entity on Noble's privacy policy. Provides related contract manufacturing services to veterinary clients and represents a directly adjacent/complementary operator in Noble's core market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noble Pharma